EUVIMEDEUVIMED entdecken
Crossref

Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults

Clotilde Allavena, Stéphanie Trancart, Lise Cuzin

Clinical Medicine. Therapeutics · 2009

DOI: 10.4137/cmt.s1088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Clotilde Allavena und 2 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atazanavir is the first azapeptide protease inhibitor. As a consequence of metabolism by the Cytochrome P450 system and excretion by drug-transporters such as P-Glycoprotein, drug interactions are considerable. They can be used to improve efficacy (ritonavir boosting) but may also cause adverse effects. Efficacy of ATV/RTV has been shown to be comparable to lopinavir/ritonavir in antiretroviral naïve patients, providing even better results in patients with high viral load. Efficacy has also been demonstrated in maintenance therapy in antiretroviral-experienced patients, and in patients with previous virologic failure, providing the best virologic response when the virus harbors less than four resistance PI mutations. The gastrointestinal tolerability and the lipid profile are better than with other PIs. The major side effect is a jaundice caused by unconjugated hyperbilirubinemia that rarely leads to discontinuation. ATV/RTV simple administration as well as tolerability may be linked with better treatment adherence. ATV/RTV is simple, potent and well tolerated. Thus it takes an important place in the treatment of HIV-infected patients, preferentially in antiretroviral-naïve or moderately pretreated populations.

Zitieren

APA

Allavena, C., Trancart, S., & Cuzin, L. (2009). Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1088

Vancouver

Allavena C, Trancart S, Cuzin L. Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1088

BibTeX
@article{Allavena2009,
  author = {Allavena, Clotilde and Trancart, Stéphanie and Cuzin, Lise},
  title = {Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults},
  journal = {Clinical Medicine. Therapeutics},
  year = {2009},
  doi = {10.4137/cmt.s1088}
}
Kostenlos starten →